Intravenous mesenchymal stem cell therapy for traumatic brain injury. by Harting, Matthew T et al.
Intravenous mesenchymal stem cell therapy for traumatic brain
injury:
Laboratory investigation
Matthew T. Harting, M.D.1, Fernando Jimenez, M.S.1, Hasan Xue, M.D.1, Uwe M. Fischer, M.D.
1, James Baumgartner, M.D.1, Pramod K. Dash, Ph.D.2,3, and Charles S. Cox Jr., M.D.1
1Departments of Pediatric Surgery, University of Texas Medical School at Houston, Texas
2Neurobiology and Anatomy, University of Texas Medical School at Houston, Texas
3The Vivian L. Smith Center for Neurologic Research, University of Texas Medical School at
Houston, Texas
Abstract
Object—Cell therapy has shown preclinical promise in the treatment of many diseases, and its
application is being translated to the clinical arena. Intravenous mesenchymal stem cell (MSC)
therapy has been shown to improve functional recovery after traumatic brain injury (TBI). Herein,
the authors report on their attempts to reproduce such observations, including detailed
characterizations of the MSC population, non–bromodeoxyuridine-based cell labeling, macroscopic
and microscopic cell tracking, quantification of cells traversing the pulmonary microvasculature, and
well-validated measurement of motor and cognitive function recovery.
Methods—Rat MSCs were isolated, expanded in vitro, immunophenotyped, and labeled. Four
million MSCs were intravenously infused into Sprague-Dawley rats 24 hours after receiving a
moderate, unilateral controlled cortical impact TBI. Infrared macroscopic cell tracking was used to
identify cell distribution. Immunohistochemical analysis of brain and lung tissues 48 hours and 2
weeks postinfusion revealed transplanted cells in these locations, and these cells were quantified.
Intraarterial blood sampling and flow cytometry were used to quantify the number of transplanted
cells reaching the arterial circulation. Motor and cognitive behavioral testing was performed to
evaluate functional recovery.
Results—At 48 hours post-MSC infusion, the majority of cells were localized to the lungs. Between
1.5 and 3.7% of the infused cells were estimated to traverse the lungs and reach the arterial circulation,
0.295% reached the carotid artery, and a very small percentage reached the cerebral parenchyma
(0.0005%) and remained there. Almost no cells were identified in the brain tissue at 2 weeks
postinfusion. No motor or cognitive functional improvements in recovery were identified.
Conclusions—The intravenous infusion of MSCs appeared neither to result in significant acute
or prolonged cerebral engraftment of cells nor to modify the recovery of motor or cognitive function.
Less than 4% of the infused cells were likely to traverse the pulmonary microvasculature and reach
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the arterial circulation, a phenomenon termed the “pulmonary first-pass effect,” which may limit the
efficacy of this therapeutic approach. The data in this study contradict the findings of previous reports
and highlight the potential shortcomings of acute, single-dose, intravenous MSC therapy for TBI.
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CELL therapy has garnered significant interest as a treatment strategy for a wide range of diseases
over the last decade. Heart disease, peripheral vascular disease, bone disease, cancer, hepatic
disease, and neurological disease have all been the focus of promising cell therapy
breakthroughs.7,15,23,24,34,40,48 Traumatic brain injury is one area in which positive preclinical
evidence has led to the initiation of early clinical trials (www.clinicaltrials.gov).
Although cell therapy has been hailed as one of the next frontiers in modern medicine, there
has been no universal agreement on many of the findings of early cell therapy work. Questions
and concerns regarding many aspects of cell therapy, including transdifferentiation,6,8,33,39,
41,44 cell labeling,5 route of administration,37 preferred cell type, and immune privilege,1,26,
35 have been raised. Furthermore, publication bias may have skewed the expectations
surrounding this treatment strategy.
Intravenous infusion has been used as the means of cell delivery in a large number of preclinical
studies16,19,27,32,43 as well as some early clinical trials.14,17,21 Intravenous delivery has been
asserted to be advantageous because of its broad distribution, ability to handle a large-volume
infusion, and ease of access.32 Nonetheless, questions have been raised regarding its ability to
transport a critical number of cells to the area of injury.28,37,42 Previous work has shown that
cell infusion via the intravenous route allows a significant number of cells to reach the
traumatically injured brain and to modulate significant functional recovery.25,27,30,32
We report on intravenously infused rat MSCs as therapy for TBI. We hypothesized that
intravenously administered rat MSCs could reach the traumatically injured rat brain in critical
numbers and improve the recovery of motor and cognitive function. We used well-
characterized rat MSCs, non–BrdU-based cell labeling, and a CCI injury model. Behavioral
outcomes were evaluated with well-validated measures of motor (rotarod, NSS, balance beam,
and foot fault) and cognitive (Morris water maze, learning paradigm) function.
Methods
Isolation, Characterization, and Labeling of Rat MSCs
All protocols involving the use of animals were in compliance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee (protocols HSC-AWC-06–038, 07–055, and
07–113). Details of the rat MSC isolation and characterization techniques have been submitted
for publication elsewhere. Briefly, we isolated MSCs from the bone marrow of Sprague-
Dawley rats. We expanded the MSCs on a fibronectin matrix in multipotent adult progenitor
cell medium.4 Flow cytometric immunophenotyping was used to ensure that the MSCs were
CD11b−, CD45−, CD29+, CD49e+, CD73+, CD90+, CD105+, and Stro-1+. Additionally, the
multilineage potential was confirmed via differentiation to chondrocytes, adipocytes, and
osteocytes. Cells between Passages 3 and 8 were used, because cells in earlier passages have
not been found to be homogeneous and cells in later passages can change their phenotype and/
or genotype. The MSCs were labeled with Qtracker 655 (immunohistochemistry and flow
cytometry of intraarterial sampling) or Qtracker 800 (Odyssey infrared imaging) cell labeling
kits (Invitrogen), according to the manufacturer’s protocol. Cell labeling efficiency was > 90%.
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Controlled Cortical Impact Injury
A CCI device (eCCI, model 6.3, Custom Design) was used to administer a unilateral brain
injury, as described previously.22 Rats were anesthetized with 4% isoflurane and a 1:1 mixture
of N2O/O2, and the head of each animal was mounted in a stereotactic frame. The head was
held in a horizontal plane, a midline incision was made for exposure, and a 7- to 8-mm
craniectomy was performed on the right cranial vault. The center of the craniectomy was placed
at the midpoint between the bregma and lambda, ~ 3 mm lateral to the midline, overlying the
temporoparietal cortex. Using a 6-mm-diameter impactor tip, we delivered to each animal a
single impact with a depth of deformation of 3.1 mm, an impact velocity of 6 m/second, and
a dwell time of 150 msec (moderately severe injury) at an angle of 10° from the vertical plane,
making the impact orthogonal to the surface of the cortex. An audible baseline monitor was
used to ensure that the location of the tip relative to the surface of the brain was consistent prior
to each impact. The blow was delivered to the parietal association cortex. Sham injury involved
anesthetizing the animals, making the midline incision, and separating the skin, connective
tissue, and aponeurosis from the cranium before closing the incision. Rat body temperature
was maintained at 37°C with the use of a heating pad. Previously obtained serial arterial blood
gases have shown that animals do not become hypoxic during this procedure.
Intravenous Administration of MSCs
Twenty-four hours after the CCI, rats were anesthetized with 4% isoflurane and O2. The right
internal jugular vein was exposed, and a silicone tubing catheter (inner diameter 0.635 mm,
outer diameter 1.19 mm) was inserted. The MSCs were infused in 1 ml of PBS vehicle by using
a 1-ml catheter flush to ensure that all cells were infused. Control rats were infused with 1 ml
of PBS vehicle only. The catheter was removed, the incision closed, and the animal allowed
to wake up. Animal respirations were closely monitored throughout the procedure and waking
period.
Immunohistochemical Analysis of Brain and Lung Tissues
At 2 days and 2 weeks after the intravenous infusion of 4 × 106 rat MSCs, coronal brain sections
were obtained for immunohistochemical analysis. After intraperitoneal ketamine injections,
the thoracic cavity was opened and room temperature PBS was infused for 15 minutes via the
left ventricle. The heart was spontaneously beating on initiation of the infusion, and the animals
were simultaneously allowed to exsanguinate via a right atrium puncture. Cold 4%
paraformaldehyde was then perfused for 15 minutes via the left ventricle. The brain was
extracted and placed in 4% paraformaldehyde at 4°C for 24–48 hours. The brain was then
embedded in 3% agarose, sectioned at 50 μm in the coronal plane by using a vibrating-blade
microtome (Leica Microsystems), stained with DAPI (Invitrogen), and placed on a slide. Two
members of the research team viewed 2 sections from the anterior penumbra, anterior injury,
central injury, posterior injury, and posterior penumbra regions of each rat brain. The cells per
coronal section were counted, and the counts were averaged and extrapolated to the entire
injury area (8 mm) and the brain.
The lungs were extracted and placed in 10% formalin at 4°C for 24 hours. The pulmonary
tissue was then paraffin embedded, sectioned at 8 μm in the coronal plane, mounted on slides,
and stained with DAPI. All tissue sections were viewed on a Nikon inverted fluorescent
microscope (model TE-2000-U).
Intravenous Cell Infusion With Intraarterial Sampling
Cells were labeled with Qtracker 655, and intravenous cannulation was achieved as described
above. Intraarterial cannulation of the common carotid artery was achieved (same size catheter
as that used in the intravenous infusions), with the tip of the catheter extending to the junction
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of the brachiocephalic trunk and the aortic arch. Rats were heparinized at 100 U/kg (~ 25 U/
rat). Control intraarterial samples were collected (250 μl/sample) prior to infusion. Cell
infusion (4 × 106 MSCs in 1 ml of vehicle) was initiated with continual intraarterial sample
collection until ~ 10 minutes after completing the infusion (~ 30 samples total, at 250 μl/
sample).
Samples were then analyzed via flow cytometry (BD LSR II, BD Biosciences) to detect labeled
cells reaching the arterial circulation. To accurately determine the number of cells reaching the
arterial circulation, a standard curve was developed by adding known amounts of labeled MSCs
(104, 5 × 104, 105, 5 × 105, and 106) to control blood samples of the same volume as the
experimental samples (250 μl). Labeled cells were counted per 20,000 total events, and each
control sample was run in triplicate. A standard curve was generated, and the resulting formula
was used to determine the cell counts per experimental sample.
Infrared Macroscopic Cell Tracking
At 2 days and 2 weeks after cell infusion the rats were killed, and the lungs, kidney, spleen,
and liver were collected. Tissues were placed on an Odyssey 2.1 infrared imaging system (LI-
COR Biosciences) and were visualized (wavelength 800 nm, resolution 84 μm, focus offset 1
mm) to identify the presence of labeled cells. The integrated intensity of each lung was obtained
by outlining the complete visualized lung and using the formula for integrated intensity: a
(ΣIi – [pixels × B]), where a is the area per pixel, ΣIi is the sum of the intensities of all pixels,
pixels is the total number of pixels, and B is the average intensity of the background.
Behavioral Training and Testing
All members of the research team involved in the behavioral testing were blinded to the
experimental groups. Cells were intravenously infused 24 hours after the CCI injury. The
optimal MSC dose is unknown, and therefore doses of 2 and 4 × 106 cells were tested. Rats
were divided into 4 groups (6 rats/group): 1) sham injury + vehicle infusion, 2) CCI + vehicle
infusion, 3) CCI + infusion of 2 × 106 MSCs, and 4) CCI + infusion of 4 × 106 MSCs.
Motor, Strength, and Reflex Tasks: Rotarod, NSS, Balance Beam, and Foot Fault
—Beginning Day 1 after injury, an accelerating rotarod was used to measure motor balance
and coordination. The rotarod consisted of a rotating spindle (diameter 10 cm). All animals
were tested in 3 trials per day on Days 1, 4, 7, and 14 after TBI. The velocity of the rod was
started at 15 rpm and was increased 3 rpm every 5 seconds. We recorded the maximum speed
maintained prior to failure, that is, a fall or an inability to stay on top of the rod.
An NSS was determined on Days 1, 4, 7, and 14 after TBI. Points are assigned for alterations
in motor function, behavior, and reflexes so that the maximal score of 14 represents severe
neurological dysfunction, whereas a score of 0 indicates normal, intact neurological function.
The indices that comprise the NSS have been described in detail elsewhere.11,32
The ability to maintain balance on a beam was assessed on Days 1, 4, 7, and 14 after TBI.
Animals were placed on a 1.5-cm-wide beam for 60 seconds or until they fell. The animals
completed 3 trials per day.
The ability to traverse chicken wire was also assessed on Days 1, 4, 7, and 14 after TBI. Animals
were placed on a chicken wire path 10 cm wide by 5 ft long, and left rear foot faults were
counted over 50 steps. Three trials per day were completed.
Cognitive Task: Morris Water Maze—Two weeks after injury, animals were tested in a
hidden-platform learning paradigm11 version of the Morris water maze task.13,36 Animals
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were tested in 4 trials per day for 5 consecutive days. Each trial was initiated by placing the
animal in 1 of 4 randomly chosen locations, facing the wall of the tank. Animals were allowed
to search for the hidden platform for a period of 60 seconds. If an animal failed to find the
platform, it was placed on the platform by the experimenter and was allowed to remain there
for 30 seconds before being returned to a warming cage for 4 minutes between trials. For each
trial, movement within the maze was monitored with a video camera linked to tracking software
(Chromotrack, San Diego Instruments). Latency to the platform was calculated as the time
necessary to locate the hidden platform. Using the tracking software, we also calculated the
time spent in the area near the platform and the time spent circle swimming.
Statistical Analysis
Differences in lung integrated intensities between experimental and control animals were
determined using a t-test. An additional ANOVA with a post hoc Dunnett test was used to
calculate differences between each of the animals. Differences in behavioral testing were
assessed using repeated measures ANOVA with a post hoc Tukey-Kramer test. All data are
expressed as the means ± SEM.
Results
Cells Identified in the Brain via Immunohistochemistry
Immunohistochemistry revealed a paucity of cells in the brain. Two days after cell infusion,
20 ± 6.65 cells (0.0005 ± 0.00017%) were identified in the brain parenchyma. Fifty percent of
these cells were identified in the injury or penumbral parenchyma, and 75% were found in the
ipsilateral hemisphere. At 2 weeks postinfusion, only 1 cell was noted in the more than 150
sections examined from all 6 rats. No cells positive for Qtracker staining were identified in the
brains of control animals.
Distribution of Infused Cells as Identified by Infrared Tracking
Infrared cell tracking 48 hours after infusion revealed that the primary location of the cells was
the pulmonary tissue (Fig. 1). The integrated intensity of the control lungs was 0.03 ± 0.03,
whereas that of the MSC-treated lungs was 2.15 ± 0.44 (p = 0.003, t-test). An ANOVA
comparing all experimental and control lungs revealed a significant difference (p = 0.037), but
post hoc Dunnett testing revealed no significant differences between experimental animals. No
differences in integrated intensity were identified in the liver, kidney, or spleen. Infrared
imaging of the brain—both as a complete organ and after sectioning—showed no detectable
changes in fluorescent or integrated intensity (images and analysis not shown).
Immunohistochemistry confirmed scores of cells in the pulmonary microvasculature (Fig. 2).
Infrared cell tracking 2 weeks after infusion revealed that the number of cells remaining in the
pulmonary tissue had decreased (Fig. 3). The integrated intensity of the control lungs was 0.66
± 0.30, whereas that of the MSC-treated lungs was 1.29 ± 0.04 (p = 0.10, t-test). Again, no
differences in integrated intensity were identified in the liver, kidney, or spleen.
Intravenous Infusion With Intraarterial Sampling
Regular arterial rat blood and Qtracker-labeled rat MSCs analyzed using flow cytometry are
shown in Fig. 4A and B, respectively. More than 95% of labeled cells were Qtracker positive
(a fluorescent intensity > 102 at a 655-nm wavelength), and 100% of whole blood cells were
Qtracker negative (fluorescent intensity < 102). Therefore, we were able to establish a
fluorescent intensity threshold of 102 for selecting positive cells from arterial sampling.
Examples of MSCs counted when 100,000 and 10,000 cells were added to a control sample of
blood are shown in Fig. 4C and D, respectively.
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Positive controls were used to generate a standard curve with the following linear formula:
MSC count = (39.86 × cells detected). This formula was used to estimate the number of cells
reaching the arterial circulation. A mean of 11,800 ± 5,865 total cells (0.295 ± 0.112%) were
found to reach the carotid arterial circulation. The majority of cells that did traverse the
pulmonary circulation reached the arterial circulation within 5 minutes after infusion (Fig. 5).
Behavioral Assessment: Motor, Strength, and Reflex Tasks
No significant improvements were seen in the rotarod (Fig. 6), NSS, balance beam, or foot
fault tests.
Behavioral Assessment: Cognitive Function
No significant improvement was seen on the Morris water maze (learning paradigm). Average
latencies are shown in Table 1.
Discussion
Our data revealed that a single intravenous dose of 4 × 106 MSCs delivered 24 hours after a
moderate TBI did not result in substantial cell engraftment or improved functional recovery.
The majority of cells were localized to pulmonary tissue. We found that 0.295% of the cells
traversed the pulmonary circulation and reached the right carotid artery, and only a very small
subset (0.0005%) of the total number of cells actually reached the brain and remained there
for 2 days. Of the cells that did reach the cerebral parenchyma, 50% were located in the area
of direct injury and the penumbral area. There was no motor or cognitive function recovery
benefit among rats receiving these cells.
Previous studies have shown greater numbers of intravenously infused MSCs reaching and
remaining in the rodent brain after TBI, as well as some measure of functional recovery.25,
27,29-32 Although our overall experimental designs were similar, there are some key
differences between the studies. Lu et al.25 and Mahmood et al.32 used rat MSCs isolated after
10 days of culture and passaged only once. We found that a population of homogeneous (>
99%) MSCs cannot be obtained until Passage 3, so we used the MSCs after Passage 3. Our
population of rat MSCs was immunocharacterized, differentiated, and from between Passages
3 and 8. Such detailed characterization is critical when comparing studies (or cell populations),
but this assertion does not mean that our population of cells is optimal for reaching the brain
or mitigating the behavioral deficits of a TBI. It is certainly possible that first-passage bone
marrow cells (a mixture of mesenchymal and hematopoietic cells), such as those used by other
authors,25,29,32 are the preferred cell mixture. Additionally, cell passage may lead to
phenotypic changes that alter the likelihood that a cell will be able to traverse the pulmonary
microvasculature. Finally, authors of some previous studies have used BrdU to label or track
cells.25 Given our concerns regarding the transfer of the BrdU label to native cells,5 we labeled
the cells in our study with the Qtracker labeling system. It is plausible that differences in cell
populations and/or cell labeling are responsible for the observed data differences between
previous studies and the present study.
Although few cells were noted in the rat brain, 50% of the identified cells appeared in the area
of injury or the penumbral area. This finding is consistent with previously collected data
showing greater cell numbers in the area of injury.32 Local disruption of the blood-brain barrier,
along with various mechanisms of homing to areas of inflammation such as the upregulation
of cell adhesion molecules,9 may be responsible for this phenomenon.
In addition, we chose a moderate CCI injury model. Although it is similar to the model
commonly applied in previous studies of intravenous MSC infusion after TBI (although others
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have used slightly less impact depth or bilateral craniotomies with unilateral injury), the degree
of injury may be important in cell survival, as recent work has revealed that transplanted neural
stem cells may survive better after mild TBI than after severe TBI.38
Our attempt to quantify the number of cells reaching the arterial circulation has some
limitations. Physiological cardiac output in rats is ~ 25 ml/minute (range 10–60 ml/minute).
With the catheter at the junction of the brachiocephalic trunk and the aortic arch, our arterial
collection rate ranged from 2–5 ml/minute, or 8–20% of the total cardiac output. Given our
observation that 0.295% of the infused cells were retrieved via the intraarterial catheter, 1.48–
3.69% of the total cells infused may reach the entire arterial circulation. Because the brain also
receives blood via the vertebral artery, slightly more than 0.295% of the cells may be reaching
the brain. An additional limitation of this intraarterial sampling method is that it likely misses
small numbers of cells that traverse the microvasculature over time. Even 48 hours after
delivery, however, numerous cells remain in the lung, and so it is unlikely that we are missing
a significant number of cells.
Cell trapping in the pulmonary microvasculature is at least partially related to cell size.
Schrepfer and colleagues37 have found that very few 4-μm microspheres are trapped by the
lung, whereas 10- and 15-μm microspheres are trapped at rates ~ 20 and ~ 30 times greater,
respectively. They also found mouse MSCs range from 15–19 μm and noted ~ 70 times more
cells trapped in the lung, relative to the 4-μm microspheres. Interestingly, these authors noted
significant decreases in the rates of microsphere and MSC trapping with vasodilator treatment.
Forward-scatter flow cytometric analysis of our results revealed that the cells that do traverse
the lungs are on the small end of the size spectrum (analysis not shown).
Although we have shown the limitations of a single intravenous dose of 4 × 106 rat MSCs in
a moderate TBI model in rodents, we believe our findings are relevant to any disease model
in which intravenous cell therapy is being investigated. The intravenous route is being used
for cell delivery in preclinical work outside of TBI, including, but not limited to, cardiac
disease,45 peripheral neuropathy,16 muscular dystrophy,18 amyotrophic lateral sclerosis,12
liver disease,20 and Kaposi sarcoma.15 The intravenous route is also being used in the treatment
of pulmonary diseases such as bleomycin-induced lung injury47 and lung tumors.46
Comparisons of cell delivery routes of have shown the intravenous method to be suboptimal,
relative to other options. Barbash and colleagues2 have compared the intravenous distribution
with left ventricular MSC infusion and found limited general engraftment with the intravenous
route due to pulmonary entrapment. Freyman and coworkers10 have compared intravenous
with intracoronary or endocardial MSC delivery in a porcine myocardial infarction model.
They also noted increased myocardial engraftment with the intracoronary and endocardial
route, as opposed to the intravenous route. They did caution that intracoronary delivery
hampers coronary blood flow. Even multipotent adult progenitor cells, a smaller, multipotent
bone marrow–derived progenitor cell type, were found to concentrate in the lung after
intravenous infusion.42 Bentzon et al.3 have demonstrated that MSCs can be efficiently and
nonspecifically trapped in the general microvasculature.
Eight clinical trials utilizing the intravenous cell delivery route are currently underway
(www.clinicaltrials.gov). The target disorders include cirrhosis, diabetes, multiple sclerosis,
myasthenia gravis, peripheral vascular disease, and TBI. More trials are being generated based
on the overwhelming majority of promising preclinical results with cell delivery via this route.
The pulmonary first-pass effect with intravenous cell delivery must be considered when
designing such trials. As ongoing research seeks a critical cell number necessary for the repair
of specific diseases or tissues, investigative efforts should be forged to minimize the pulmonary
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first-pass effect—perhaps increased cell delivery, small cell selection, alteration of adhesion
markers, rheological agent use, or pulmonary vasodilation.
Conclusions
We showed that a single intravenous dose of 4 × 106 MSCs delivered 24 hours after a moderate
TBI does not lead to substantial cell engraftment or improved functional recovery. This result
is largely attributable to the pulmonary first-pass effect, in which the pulmonary
microvasculature denies significant cell passage into the arterial circulation. We estimate that
only 1.48–3.69% of infused cells reach the arterial circulation, only 0.295% reach the right
carotid artery, and only 0.0005% reach and remain in the traumatically injured brain. An
accurate and complete understanding of the strengths and weaknesses of intravenous cell
delivery is paramount to maximizing the cell therapy delivery strategy.
Abbreviations used in this paper
ANOVA analysis of variance
BrdU bromodeoxyuridine
CCI controlled cortical impact
MSC mesenchymal stem cell
NSS neurological severity score
PBS phosphate-buffered saline
TBI traumatic brain injury
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Fig. 1.
Upper: Infrared images (image resolution: 84 μm; focus offset: 1 mm) demonstrating
intravenously infused MSCs in the lungs, kidney, spleen, and liver of rats 48 hours after the
infusion of 4 × 106 MSCs (experimental rats 1–4) or PBS vehicle (Control). Lower: Bar graph
showing the lung integrated intensities in the experimental animals, which were significantly
different from those in controls (p = 0.003, t-test).
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Fig. 2.
A and B: Photomicrographs showing numerous MSCs (Qtracker labeled) in the pulmonary
tissue 48 hours after intravenous infusion. Cell nuclei are revealed by DAPI staining (blue)
and MSCs by Qtracker 655 (red). Arrowheads indicate representative MSCs.
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Fig. 3.
Upper: Infrared images (image resolution: 84 μm; focus offset: 1 mm) revealing the lungs,
kidney, spleen, and liver of rats 2 weeks after the intravenous infusion of 4 × 106 MSCs
(experimental rats 1–3) or vehicle (Control). Although some cells remain in the pulmonary
tissue, there are significantly fewer than those seen 48 hours postinfusion. Lower: Bar graph
showing lung integrated intensities of the experimental animals, which were not significantly
different from those from controls (p = 0.10, t-test).
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Fig. 4.
Flow cytometric scatterplot demonstrating rat whole blood cells (A) and Qtracker labeled rat
MSCs (B). The red line shows the positive threshold (102) used to distinguish infused MSCs
from other cells (> 95% of MSCs). The clear difference in intensity of rat blood (A) versus
MSCs (B) allowed recognition of infused cells by flow cytometry. To generate a standard
curve, MSC counts were obtained after adding known quantities of MSCs to control samples.
Example scatterplots showing the effects of 100,000 MSCs (C) and 10,000 MSCs (D) added
to control samples of rat blood. The number of cells with a fluorescent intensity > 102, after
collecting 20,000 total events, was plotted against the known MSC number to generate the
standard curve. APC-A = allophycocyanine–A channel; SSC-A = side scatter–A channel.
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Fig. 5.
Bar graph showing Qtracker-labeled MSCs in intraarterial blood samples run through a flow
cytometer. Four million rat MSCs (Qtracker labeled) were infused via the internal jugular vein
(5 rats), and blood was continuously sampled from the common carotid artery over the
subsequent 10 minutes. IV = intravenous.
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Fig. 6.
Graphs showing the results of rotarod (A), NSS (B), balance beam (C), and foot fault (D)
testing. There were no significant differences between the CCI groups. Rotarod maximum
speed is the highest rpm during which the rat could stay on the top of the rotating rod. Time
on beam was measured from the time the animal was placed on the beam until the animal fell
off and hit the safe landing area. Foot faults were counted when the left rear paw dropped below
the chicken wire (out of 25 steps). Sham, 6 rats; CCI + vehicle, 5 rats; CCI + 2 × 106 MSCs,
4 rats; CCI + 4 × 106 MSCs, 6 rats. s = seconds.
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